Literature DB >> 23982958

YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment.

Diana Morales1, Rosa Hechavarria, Valerie Wojna, Summer F Acevedo.   

Abstract

YWHAE (14-3-3ε) protein levels are considered to be a reliable biomarker for neurodegeneration. The YWHAE protein interacts both directly and indirectly with human immunodeficiency virus (HIV) accessory proteins, leading to cell death. The purpose of this study was to examine the relationship between YWHAE polymorphisms and HIV-associated neurocognitive disorder (HAND) and the relationship between YWHAE protein levels and HAND. A cross-sectional study using random samples of HIV-seropositive (n = 20) and HIV-seronegative (controls) (n = 16) women from the Hispanic-Latino Longitudinal Cohort of Women was conducted. Individuals who are HIV-seropositive and heterozygous at the rs4790084/rs1204828 loci in the YWHAE gene were 3× more likely to display reduced cognitive functioning, to have received a HAND diagnosis, and to have less YHWAE protein expressed than homozygotes. Western blots from cerebral spinal fluid indicate that the HIV-seropositive women with HAND expressed 4.5× less YWHAE compared to HIV-seropositive cognitively normal women (94 % sensitivity, 84 % specificity; HIV-seropositive vs. controls). Therefore, polymorphism in YWHAE may be a genetic risk factor for HAND and levels of YWHAE protein are a likely biomarker for neurocognitive status in HIV-seropositive women.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23982958      PMCID: PMC3962987          DOI: 10.1007/s13365-013-0200-z

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  41 in total

Review 1.  14-3-3 proteins in the nervous system.

Authors:  Daniela Berg; Carsten Holzmann; Olaf Riess
Journal:  Nat Rev Neurosci       Date:  2003-09       Impact factor: 34.870

2.  Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 3.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

4.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies.

Authors:  G Hsich; K Kenney; C J Gibbs; K H Lee; M G Harrington
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

6.  Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein.

Authors:  L J Zhao; S Mukherjee; O Narayan
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

7.  14-3-3sigma expression and prognostic value in patients with epithelial ovarian carcinoma: a high throughput tissue microarray analysis.

Authors:  P Mhawech-Fauceglia; F R Herrmann; C Andrews; S South; A Beck; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2008-12-09       Impact factor: 4.424

8.  Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease.

Authors:  Michael D Geschwind; Jennifer Martindale; Deborah Miller; Stephen J DeArmond; Jane Uyehara-Lock; David Gaskin; Joel H Kramer; Nicholas M Barbaro; Bruce L Miller
Journal:  Arch Neurol       Date:  2003-06

9.  Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease.

Authors:  Mauricio Torres; Luis Cartier; José Manuel Matamala; Nancy Hernández; Ute Woehlbier; Claudio Hetz
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

10.  14-3-3 theta binding to cell cycle regulatory factors is enhanced by HIV-1 Vpr.

Authors:  Diane L Bolton; Robert A Barnitz; Keiko Sakai; Michael J Lenardo
Journal:  Biol Direct       Date:  2008-04-29       Impact factor: 4.540

View more
  6 in total

1.  miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway.

Authors:  Jiafu Zhao; Houqiang Xu; Zhiqiang Duan; Xiang Chen; Zheng Ao; Yinglian Chen; Yong Ruan; Mengmeng Ni
Journal:  Cancer Manag Res       Date:  2020-07-31       Impact factor: 3.989

2.  Differential expression profile of long non-coding RNAs during differentiation of cardiomyocytes.

Authors:  Shasha Zhu; Xiaoshan Hu; Shuping Han; Zhangbin Yu; Yuzhu Peng; Jingai Zhu; Xuehua Liu; Lingmei Qian; Chun Zhu; Mengmeng Li; Guixian Song; Xirong Guo
Journal:  Int J Med Sci       Date:  2014-03-28       Impact factor: 3.738

3.  Immune Responses in the Central Nervous System Are Anatomically Segregated in a Non-Human Primate Model of Human Immunodeficiency Virus Infection.

Authors:  Barbara Tavano; Vicky Tsipouri; Gareth A D Hardy; Caroline M Royle; Michael R Keegan; Dietmar Fuchs; Steven Patterson; Neil Almond; Neil Berry; Claire Ham; Deborah Ferguson; Adriano Boasso
Journal:  Front Immunol       Date:  2017-03-30       Impact factor: 7.561

Review 4.  Transcriptomic and Genetic Profiling of HIV-Associated Neurocognitive Disorders.

Authors:  Daniel Ojeda-Juárez; Marcus Kaul
Journal:  Front Mol Biosci       Date:  2021-10-29

Review 5.  Host genetic factors predisposing to HIV-associated neurocognitive disorder.

Authors:  Asha R Kallianpur; Andrew J Levine
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

6.  Assessing health-related resiliency in HIV+ Latin women: Preliminary psychometric findings.

Authors:  Gladys J Jimenez-Torres; Valerie Wojna; Ernesto Rosario; Rosa Hechevarría; Ada M Alemán-Batista; Miriam Ríos Matos; Alok Madan; Richard L Skolasky; Summer F Acevedo
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.